O	0	10	Calretinin	Calretinin	NN	B-NP
O	10	11	.	.	.	O

O	12	13	A	A	DT	B-NP
O	14	23	selective	selective	JJ	I-NP
O	24	30	marker	marker	NN	I-NP
O	31	33	of	of	IN	B-PP
O	34	40	normal	normal	JJ	B-NP
O	41	44	and	and	CC	I-NP
B-Cell	45	55	neoplastic	neoplastic	JJ	I-NP
I-Cell	56	67	mesothelial	mesothelial	JJ	I-NP
I-Cell	68	73	cells	cell	NNS	I-NP
O	74	76	in	in	IN	B-PP
B-Organism_substance	77	83	serous	serous	JJ	B-NP
I-Organism_substance	84	93	effusions	effusion	NNS	I-NP
O	93	94	.	.	.	O

O	96	105	OBJECTIVE	OBJECTIVE	NN	B-NP
O	105	106	:	:	:	O
O	107	109	To	To	TO	B-VP
O	110	118	document	document	VB	I-VP
O	119	123	that	that	IN	B-SBAR
O	124	125	a	a	DT	B-NP
O	126	136	polyclonal	polyclonal	JJ	I-NP
B-Organism_substance	137	146	antiserum	antiserum	NN	I-NP
O	147	149	to	to	TO	B-PP
O	150	160	calretinin	calretinin	NN	B-NP
O	160	161	,	,	,	O
O	162	163	a	a	DT	B-NP
O	164	166	29	29	CD	I-NP
O	166	167	-	-	HYPH	I-NP
O	167	169	kd	kd	NN	I-NP
O	170	177	calcium	calcium	NN	I-NP
O	177	178	-	-	HYPH	O
O	178	185	binding	bind	VBG	B-NP
O	186	193	protein	protein	NN	I-NP
O	193	194	,	,	,	O
O	195	207	consistently	consistently	RB	B-ADVP
O	208	217	decorates	decorate	VBZ	B-VP
O	218	224	normal	normal	JJ	B-NP
O	225	228	and	and	CC	I-NP
B-Cell	229	234	tumor	tumor	NN	I-NP
I-Cell	235	246	mesothelial	mesothelial	JJ	I-NP
I-Cell	247	252	cells	cell	NNS	I-NP
O	253	255	in	in	IN	B-PP
B-Cell	256	265	cytologic	cytologic	JJ	B-NP
I-Cell	266	278	preparations	preparation	NNS	I-NP
O	278	279	.	.	.	O

O	280	285	STUDY	STUDY	NN	B-NP
O	286	292	DESIGN	DESIGN	NN	I-NP
O	292	293	:	:	:	O
O	294	300	Thirty	Thirty	CD	B-NP
O	300	301	-	-	HYPH	I-NP
O	301	306	three	three	CD	I-NP
O	307	315	archival	archival	JJ	I-NP
B-Cell	316	325	cytologic	cytologic	JJ	I-NP
I-Cell	326	335	specimens	specimen	NNS	I-NP
O	336	340	from	from	IN	B-PP
O	341	346	eight	eight	CD	B-NP
O	347	355	patients	patient	NNS	I-NP
O	356	360	with	with	IN	B-PP
O	361	375	histologically	histologically	RB	B-NP
O	376	385	confirmed	confirm	VBN	I-NP
B-Cancer	386	395	malignant	malignant	JJ	I-NP
I-Cancer	396	408	mesothelioma	mesothelioma	NN	I-NP
O	409	412	and	and	CC	O
O	413	415	13	13	CD	B-NP
O	416	420	from	from	IN	B-PP
O	421	429	patients	patient	NNS	B-NP
O	430	434	with	with	IN	B-PP
B-Organism_substance	435	445	metastatic	metastatic	JJ	B-NP
I-Organism_substance	446	452	serous	serous	JJ	I-NP
I-Organism_substance	453	462	effusions	effusion	NNS	I-NP
O	463	467	were	be	VBD	B-VP
O	468	477	destained	destaine	VBN	I-VP
O	478	481	and	and	CC	O
O	482	486	then	then	RB	B-VP
O	487	500	immunostained	immunostaine	VBN	I-VP
O	501	505	with	with	IN	B-PP
O	506	520	anticalretinin	anticalretinin	NN	B-NP
B-Organism_substance	521	530	antiserum	antiserum	NN	I-NP
O	530	531	.	.	.	O

O	532	535	For	For	IN	B-PP
O	536	549	investigation	investigation	NN	B-NP
O	550	552	of	of	IN	B-PP
B-Cell	553	557	cell	cell	NN	B-NP
I-Cell	558	569	suspensions	suspension	NNS	I-NP
O	569	570	,	,	,	O
O	571	575	four	four	CD	B-NP
B-Organism_substance	576	583	pleural	pleural	JJ	I-NP
I-Organism_substance	584	590	fluids	fluid	NNS	I-NP
O	591	595	were	be	VBD	B-VP
O	596	605	incubated	incubate	VBN	I-VP
O	606	610	with	with	IN	B-PP
O	611	625	anticalretinin	anticalretinin	NN	B-NP
B-Organism_substance	626	635	antiserum	antiserum	NN	I-NP
O	635	636	.	.	.	O

O	637	642	After	After	IN	B-PP
O	643	661	cytocentrifugation	cytocentrifugation	NN	B-NP
O	662	665	the	the	DT	B-NP
B-Cell	666	675	specimens	specimen	NNS	I-NP
O	676	680	were	be	VBD	B-VP
O	681	688	stained	stain	VBN	I-VP
O	689	691	in	in	IN	B-PP
O	692	702	accordance	accordance	NN	B-NP
O	703	707	with	with	IN	B-PP
O	708	711	the	the	DT	B-NP
O	712	720	alkaline	alkaline	NN	I-NP
O	721	732	phosphatase	phosphatase	NN	I-NP
O	733	737	anti	anti	AFX	O
O	737	738	-	-	HYPH	O
O	738	746	alkaline	alkaline	NN	B-NP
O	747	758	phosphatase	phosphatase	NN	I-NP
O	759	760	(	(	(	O
O	760	765	APAAP	APAAP	NN	B-NP
O	765	766	)	)	)	O
O	767	773	method	method	NN	B-NP
O	773	774	.	.	.	O

O	775	778	For	For	IN	B-PP
O	779	787	electron	electron	NN	B-NP
O	788	799	microscopic	microscopic	JJ	I-NP
O	800	811	examination	examination	NN	I-NP
O	812	815	the	the	DT	B-NP
B-Cell	816	820	cell	cell	NN	I-NP
I-Cell	821	832	suspensions	suspension	NNS	I-NP
O	833	837	were	be	VBD	B-VP
O	838	842	then	then	RB	I-VP
O	843	852	incubated	incubate	VBN	I-VP
O	853	857	with	with	IN	B-PP
O	858	862	gold	gold	NN	B-NP
O	862	863	-	-	HYPH	B-NP
O	863	870	labeled	label	VBN	I-NP
O	871	881	antirabbit	antirabbit	NN	I-NP
O	882	890	antibody	antibody	NN	I-NP
O	890	891	.	.	.	O

O	892	899	RESULTS	RESULTS	NNS	B-NP
O	899	900	:	:	:	O
O	901	904	The	The	DT	B-NP
O	905	915	diagnostic	diagnostic	JJ	I-NP
O	916	927	sensitivity	sensitivity	NN	I-NP
O	928	930	of	of	IN	B-PP
O	931	935	this	this	DT	B-NP
O	936	939	new	new	JJ	I-NP
O	940	958	immunocytochemical	immunocytochemical	JJ	I-NP
O	959	967	approach	approach	NN	I-NP
O	968	975	reached	reach	VBD	B-VP
O	976	979	100	100	CD	B-NP
O	979	980	%	%	NN	I-NP
O	981	984	for	for	IN	B-PP
O	985	988	the	the	DT	B-NP
O	989	994	eight	eight	CD	I-NP
B-Cancer	995	1004	malignant	malignant	JJ	I-NP
I-Cancer	1005	1018	mesotheliomas	mesothelioma	NNS	I-NP
O	1019	1031	investigated	investigate	VBN	B-VP
O	1031	1032	.	.	.	O

O	1033	1037	Only	Only	RB	B-NP
O	1038	1039	3	3	CD	I-NP
O	1040	1042	of	of	IN	B-PP
O	1043	1046	the	the	DT	B-NP
O	1047	1049	13	13	CD	I-NP
B-Cancer	1050	1065	adenocarcinomas	adenocarcinoma	NNS	I-NP
O	1066	1076	metastatic	metastatic	JJ	B-ADJP
O	1077	1079	to	to	TO	B-PP
O	1080	1083	the	the	DT	B-NP
B-Tissue	1084	1090	serous	serous	JJ	I-NP
I-Tissue	1091	1100	membranes	membrane	NNS	I-NP
O	1101	1109	included	include	VBN	B-VP
O	1110	1112	in	in	IN	B-PP
O	1113	1117	this	this	DT	B-NP
O	1118	1123	study	study	NN	I-NP
O	1124	1128	were	be	VBD	B-VP
O	1129	1135	weakly	weakly	RB	B-ADJP
O	1136	1144	reactive	reactive	JJ	I-ADJP
O	1144	1145	,	,	,	O
O	1146	1156	accounting	account	VBG	B-VP
O	1157	1160	for	for	IN	B-PP
O	1161	1163	81	81	CD	B-NP
O	1163	1164	%	%	NN	I-NP
O	1165	1176	specificity	specificity	NN	I-NP
O	1176	1177	.	.	.	O

O	1178	1185	Binding	Binding	NN	B-NP
O	1186	1188	of	of	IN	B-PP
O	1189	1203	anticalretinin	anticalretinin	NN	B-NP
B-Organism_substance	1204	1213	antiserum	antiserum	NN	I-NP
O	1214	1216	to	to	TO	B-PP
O	1217	1223	living	live	VBG	B-VP
B-Cell	1224	1235	mesothelial	mesothelial	JJ	B-NP
I-Cell	1236	1241	cells	cell	NNS	I-NP
O	1242	1245	was	be	VBD	B-VP
O	1246	1258	consistently	consistently	RB	I-VP
O	1259	1269	documented	document	VBN	I-VP
O	1270	1272	in	in	IN	B-PP
O	1273	1276	all	all	DT	B-NP
O	1277	1281	four	four	CD	I-NP
O	1282	1287	cases	case	NNS	I-NP
O	1288	1300	investigated	investigate	VBN	B-VP
O	1300	1301	.	.	.	O

O	1302	1312	CONCLUSION	CONCLUSION	NN	B-NP
O	1312	1313	:	:	:	O
O	1314	1324	Calretinin	Calretinin	NN	B-NP
O	1325	1327	is	be	VBZ	B-VP
O	1328	1329	a	a	DT	B-NP
O	1330	1334	very	very	RB	I-NP
O	1335	1341	useful	useful	JJ	I-NP
O	1342	1348	marker	marker	NN	I-NP
O	1349	1352	for	for	IN	B-PP
O	1353	1361	positive	positive	JJ	B-NP
O	1362	1376	identification	identification	NN	I-NP
O	1377	1379	of	of	IN	B-PP
O	1380	1386	normal	normal	JJ	B-NP
O	1387	1390	and	and	CC	I-NP
B-Cell	1391	1396	tumor	tumor	NN	I-NP
I-Cell	1397	1408	mesothelial	mesothelial	JJ	I-NP
I-Cell	1409	1414	cells	cell	NNS	I-NP
O	1415	1417	in	in	IN	B-PP
B-Organism_substance	1418	1424	serous	serous	JJ	B-NP
I-Organism_substance	1425	1434	effusions	effusion	NNS	I-NP
O	1434	1435	.	.	.	O

